Mykronor (Noradrenaline Tartrate)

Noradrenaline acts as a direct agonist at alpha‑adrenergic receptors, causing peripheral blood vessels to constrict, which raises systemic vascular resistance. At higher concentrations it also stimulates beta‑1 receptors, enhancing heart contractility and cardiac output, together improving perfusion during shock.

The dose of Mykronor is individualized by the treating physician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Clinicians titrate the intravenous infusion to achieve the desired mean arterial pressure while monitoring for adverse effects.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mykronor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Mykronor (noradrenaline) is considered a first‑line vasopressor for most shock states because of its potent alpha‑adrenergic vasoconstriction and modest beta‑1 activity. Alternatives such as dopamine or phenylephrine may have different receptor profiles, but noradrenaline generally offers a more predictable increase in blood pressure with fewer tachyarrhythmic effects.

Mykronor should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Mykronor is supplied as an injectable solution for intravenous use only. It is typically administered via a controlled infusion pump, allowing precise titration of the dose to maintain target blood pressure while continuous hemodynamic monitoring is performed.

Serious risks include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, and tissue necrosis if the drug extravasates from the vein. Continuous monitoring of blood pressure, cardiac rhythm, and infusion site is essential to detect and manage these complications promptly.

Mykronor is contraindicated in patients with known hypersensitivity to noradrenaline or any excipients, and it should be used with extreme caution in individuals with uncontrolled tachyarrhythmias, severe coronary artery disease, or peripheral vascular disease where excessive vasoconstriction could cause harm.